{
    "clinical_study": {
        "@rank": "153002", 
        "acronym": "CLI", 
        "arm_group": [
            {
                "arm_group_label": "ASCT01", 
                "arm_group_type": "Experimental", 
                "description": "CD34+ and CD45+ cells in ASCT01 preparation"
            }, 
            {
                "arm_group_label": "Placebo (0.9 % sterile saline solution)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo(0.9 % sterile saline solution)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the safety and efficacy of intra-arterial infusion and intramuscular\n      injection of an autologous, bone marrow-derived stem cell preparation (ASCT01) versus\n      placebo in patients with critical limb ischemia who have exhausted all medical and surgical\n      therapeutic options. The safety and tolerability will be evaluated by regular monitoring of\n      the general physical condition, vital signs, and the occurrence of AE and SAE, respectively.\n      Furthermore, the standard biochemical and blood variables (red and white blood cell counts,\n      Hb, Ht, platelets, sodium, potassium, chloride, calcium, phosphor, ASAT, ALAT, bilirubin,\n      total protein, albumin, AP, cholesterol (LDL,HDL), triglycerides, urea and creatinine,\n      immunoglobulins, HBA1c, C-peptide) will be checked before the treatment as well as 30 and 90\n      days after the treatment."
        }, 
        "brief_title": "Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Critical Limb Ischemia", 
        "condition_browse": {
            "mesh_term": "Ischemia"
        }, 
        "detailed_description": {
            "textblock": "Efficacy will be determined by number of collateral arteries as assessed magnetic resonance\n      angiography at baseline and again at 3 months, rate of major amputation (above the ankle) of\n      the affected limb within 3 months or an unchanged critical limb ischemia of the affected\n      limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle\n      pressure.Efficacy endpoint is at 3 months. Clinical endpoints and safety will be measured\n      through 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients in the age group of 18-75 yrs.\n\n          2. Established CLI (confirmed by Rutherford 4 to 5 or Fontaine III-IV to the\n             recommendations of the TASC) with angiographic evidence of significant with\n             infra-inguinal arterial occlusive disease\n\n          3. Ankle Brachial Pressure Index (ABI) \u2264 0.6 or the absolute ankle systolic blood\n             pressure < 60 mm Hg or TcPO2 <20 mmHg without tissue loss or TcPO2 <40 mmHg if there\n             is tissue loss or alternatively toe Brachial Pressure Index (TBI) less 0.5 or the\n             absolute toe blood pressure less than 50 mm Hg.\n\n          4. No surgical or interventional option for revascularization and no response to best\n             standard care delivered as confirmed by a physician.\n\n          5. No immediate life-threatening complication from CLI, which would demand immediate\n             amputation.\n\n          6. Patients who are able to understand the requirements of the study, and willing to\n             provide voluntary written informed consent, abide by the study requirements, and\n             agree to return for required follow-up visits.\n\n          7. Number of stem cells isolated from bone marrow (> 2 million per sample CD34+ and\n             CD45+) for control purpose only. Subjects whose samples yield fewer cells will still\n             be included in the trial and statistically evaluated as an outlying variable.\n\n          8. Viability of isolated stem cells > 70% of CD 34+ and CD45+.(for control purpose only)\n\n          9. On optimal medical therapy\n\n         10. If diabetic, HgbA1c <10%\n\n        Exclusion Criteria:\n\n          1. Acute life threatening complication of limb ischemia with the need for immediate limb\n             amputation to avoid death or clinical deterioration\n\n          2. Patients with confirmed Rutherford 6 condition with extensive tissue damage\n\n          3. Patients with documented terminal illness or cancer or any concomitant disease\n             process with a life expectancy of less than 6 months.\n\n          4. Patients with a history of severe alcohol or drug abuse within 3 months of screening.\n\n          5. Known bone marrow diseases which preclude transplantation.\n\n          6. End-stage renal failure on regular dialysis treatment\n\n          7. Patients already enrolled in another investigational drug trial or completed within 3\n             months.\n\n          8. Pregnancy.\n\n          9. Patients tested positive for serology (anti-HIV 1, Anti-HIV 2, anti-HCV, anti-HBc,\n             HBs-antigen, or TPA)*\n\n         10. Myocardial infarction / CVA / TIA within 3 months prior to enrollment\n\n         11. Revascularization of the target limb within 3 months prior to enrollment.\n\n         12. Laboratory values as shown below*\n\n         13. Currently taking immunosuppressive agents\n\n         14. In diabetic subjects, a diagnosis of proliferative retinopathy\n\n         15. Patients with infected ulcers or systemic infections *Laboratory Values: Hemoglobin\n             <10 g/dL Platelet count <100,000/microL ALT  >60 U/L AST   >60 U/L Bilirubin  >1.0\n             mg/dL INR   >1.3 APTT   >40 second"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867190", 
            "org_study_id": "IND 15069"
        }, 
        "intervention": [
            {
                "arm_group_label": "ASCT01", 
                "description": "Single Administration of the entire ASCT01 preparation  at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.5 ml each intramuscular route", 
                "intervention_name": "ASCT01 (Autologous Stem Cell Transplantation)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo (0.9 % sterile saline solution)", 
                "intervention_name": "placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "CLI", 
        "lastchanged_date": "May 31, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "Cardiovascular Research Institute, University of Kansas Medical Center"
                }, 
                "investigator": {
                    "last_name": "Buddahdeb Dawn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "Cardiovascular Research Institute, University of Kansas Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single-center Randomized Double-blind Placebo-controlled Phase 2 Proof of Concept Study to Assess the Efficacy and Safety of ASCT01 in Patients With Critical Limb Ischemia", 
        "overall_contact": {
            "email": "paulsmrtc@aol.com", 
            "last_name": "Paul T Sudhakar, M.S. Pharm", 
            "phone": "816-507-8249"
        }, 
        "overall_official": {
            "affiliation": "Lifecells, LLC.", 
            "last_name": "Paul T Sudhakar, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome variable is \"treatment failure\" defined as major amputation (above the ankle) of the affected limb within 3 months or an unchanged critical limb ischemia of the affected limb after 3 months defined as less than 15% change in tcPO2 or ABI or absolute ankle pressure.", 
            "measure": "To assess the efficacy and safety of intra-arterial infusion and intramuscular injection of ASCT01 on the combined primary endpoint of major amputation (above the ankle) or persisting critical limb ischemia (no clinical or perfusion improvement).", 
            "safety_issue": "Yes", 
            "time_frame": "primary outcome measured at 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867190"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Lifecells, LLC.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lifecells, LLC.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}